Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Artivion, Inc. Common Stock (NY:AORT)

21.29 +0.07 (+0.35%)
Delayed Quote Updated: 1:58 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Artivion, Inc. Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
1 Small-Cap Stock with Exciting Potential and 2 We Turn Down
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ... 
Via StockStory
News headline image
1 Safe-and-Steady Stock with Competitive Advantages and 2 Facing Headwinds
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. Lu... 
Via StockStory
Topics Economy
News headline image
2 Growth Stocks with All-Star Potential and 1 We Find Risky
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va... 
Via StockStory
News headline image
3 Healthcare Stocks We’re Skeptical Of
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva... 
Via StockStory
Artivion Inc (NYSE:AORT) Catches the GARP Eye With Affordable Growth Screen ↗
Via Chartmill
News headline image
3 Profitable Stocks We Approach with Caution
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
Via StockStory
News headline image
3 Reasons to Avoid AORT and 1 Stock to Buy Instead
What a brutal six months it’s been for Artivion. The stock has dropped 29.1% and now trades at $25.57, rattling many shareholders. This may have investors wo... 
Via StockStory
Topics Supply Chain
News headline image
3 Russell 2000 Stocks Walking a Fine Line
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resou... 
Via StockStory
Topics Energy
News headline image
1 High-Flying Stock to Own for Decades and 2 Facing Challenges
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo... 
Via StockStory
News headline image
Why Artivion (AORT) Stock Is Trading Up Today
What Happened? Shares of medical device company Artivion (NYSE:AORT) jumped 2.5% in the afternoon session after Canaccord Genuity raised its price target on ... 
Via StockStory
Topics Earnings
News headline image
Artivion (AORT) Q2 2026 Earnings Call Transcript ↗
Revenue grew 9% as heart valve and stent graft products drove results. 
Via The Motley Fool
Topics Earnings
News headline image
5 Revealing Analyst Questions From Artivion’s Q2 Earnings Call
Artivion’s second quarter results were well received by the market, with performance driven by accelerating growth in its stent graft and On-X heart valve po... 
Via StockStory
Topics Earnings
News headline image
Artivion Q2 Earnings Call Highlights ↗
Artivion (NYSE:AORT) reported second-quarter 2026 revenue of $125.8 million, up 9% year over year on a constant-currency basis, as growth in stent grafts and On-X heart valves offset modest declines in... 
Via MarketBeat
Topics Earnings
News headline image
AORT Q2 Deep Dive: Product Momentum and Pipeline Expansion Support Positive Outlook
Medical device company Artivion (NYSE:AORT) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 11.3% year on year to $125.8 ... 
Via StockStory
News headline image
Artivion (NYSE:AORT) Delivers Strong Q2 CY2026 Numbers
Medical device company Artivion (NYSE:AORT) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 11.3% year on year to $125.8 mil... 
Via StockStory
News headline image
Artivion (AORT) To Report Earnings Tomorrow: Here Is What To Expect
Medical device company Artivion (NYSE:AORT) will be reporting earnings this Thursday after the bell. Here’s what to expect. Artivion met analysts’ revenue ex... 
Via StockStory
News headline image
3 Healthcare Stocks with Questionable Fundamentals
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on... 
Via StockStory
News headline image
3 Small-Cap Stocks We Keep Off Our Radar
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th... 
Via StockStory
News headline image
3 Reasons to Sell AORT and 1 Stock to Buy Instead
Artivion’s stock price has taken a beating over the past six months, shedding 43.8% of its value and falling to $24.10 per share. This was partly due to its ... 
Via StockStory
Topics Supply Chain
News headline image
3 Stocks Under $50 with Warning Signs
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha... 
Via StockStory
News headline image
2 Growth Stocks Set to Flourishand 1 We Ignore
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va... 
Via StockStory
News headline image
3 Profitable Stocks We Keep Off Our Radar
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
Topics Electric Vehicles World Trade
News headline image
1 of Wall Street’s Favorite Stocks with Solid Fundamentals and 2 We Question
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember... 
Via StockStory
News headline image
Q1 Earnings Outperformers: Artivion (NYSE:AORT) And The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Artivion (NYSE:AORT) and its ... 
Via StockStory
News headline image
3 High-Flying Stocks Walking a Fine Line
“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ... 
Via StockStory
News headline image
3 Healthcare Stocks We Keep Off Our Radar
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recentl... 
Via StockStory
News headline image
Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System
From Endospan
Via Business Wire
News headline image
Crafting title options within editorial guidelines An ETF Shop Just Made a Beaten-Down Medtech Its Top Holding ↗
Artivion delivers advanced cardiovascular and vascular solutions to healthcare providers worldwide through its proprietary medical devices. 
Via The Motley Fool
Topics Bonds ETFs
News headline image
5 Insightful Analyst Questions From Artivion’s Q1 Earnings Call
Artivion’s first quarter results for 2026 were met with a significant negative market reaction, with investors responding to shortfalls in adjusted profitabi... 
Via StockStory
Topics Earnings
News headline image
Artivion Q1 Earnings Call Highlights ↗
Artivion (NYSE:AORT) executives said the company delivered double-digit revenue and adjusted EBITDA growth in the first quarter of 2026, while also lowering its full-year revenue outlook due primarily... 
Via MarketBeat
Topics Earnings
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.